Click for quick access:


The NETest



Wren Lab equipment

Our Diagnostics and Your Diagnosis

Non-invasive tests that use mRNA to detect cancer in real-time, and help tailor and monitor treatment.

Tissue biopsies, conventional biomarkers, and imaging, such as CT scans or MRIs, provide important information that can lead to preliminary diagnoses of neuroendocrine cancer or prostate cancer. However, there are drawbacks, as they can be invasive, time-consuming, or lacking in accuracy and specificity.

Our diagnostics use mRNA—the body’s cellular messaging system—to identify tumor activity and to better understand the disease state of cancer. mRNA is found in an easily obtained blood sample, can be analyzed and reported on within 48 hours, and offers unmatched accuracy (>95% for NET, >90% for Prostate) and specificity (>90% for NET, >95% for Prostate).

Blood mRNA and Your Cancer Diagnosis

Since our founding, we’ve focused on measuring mRNA for our tests. It is a proven diagnostic as the first mRNA assay was utilized in 1998. It contains powerful molecular information that, when used by our AI-driven analytics, provides significant insight into disease activity*. It’s robust and stable, and when combined with our sampling buffer, it transports well from the collection site to our lab.

Well-Researched and Expanding Usage

Our approach to cancer diagnostics—using mRNA assessment with the help of artificial intelligence and multianalyte analysis—is backed by more than 60 peer-reviewed articles. Additionally, leading oncologists in medical centers across the U.S. have used the NETest over 10,000 times.

*Disease activity is defined as the calculated risk of highly active disease as measured by an algorithm based on gene expression data. Test results should be used in conjunction with standard clinical assessment.

Molecular Diagnostics

About Our Science

The diagnostics offered by Wren Laboratories, which include a blood-based neuroendocrine cancer test (NETest), a PRRT treatment predictor quotient (NETest PPQ), a saliva-based Covid-19 test, and a soon-to-be-available prostate cancer test (PROSTest), are all based on the assessment of mRNA found in effortlessly-obtained body fluids: blood and saliva. We use state-of-the-art standardized laboratory techniques to process these liquid biopsies before assessing them with a suite of gene assays and proprietary algorithms we have developed.

Proven Performance

 mRNA Molecular Testing

Our molecular cancer diagnostics are unsurpassed in accuracy while delivering high levels of sensitivity and specificity to minimize incorrect diagnoses.


The National Cancer Institute, peer-reviewed research and our decades of experience indicate mRNA is unsurpassed for testing accuracy.


The NETest has exhibited 98% sensitivity while the PROSTest has exhibited 95% sensitivity.


NETest has shown specificity levels in excess of 95%, while preliminary results for the PROSTest indicate a 90% specificity.

The NETest

A liquid biopsy NET diagnostic to help doctors better understand and manage neuroendocrine cancer

Clinically available since 2014 and now widely used for neuroendocrine cancer patients in cancer clinics and medical centers throughout the US, the NETest is a blood-based neuroendocrine cancer diagnostic that uses mRNA and a proprietary 51-gene assessment to help diagnose, recommend treatment, and then monitor therapeutic progress in real-time.

Quick and non-invasive, results from our liquid biopsy can be communicated within 48 hours after receipt of a blood sample. After analysis with our multianalyte algorithm suite, we produce a personalized risk score that will help patients and doctors to:

Understand the disease state of the neuroendocrine tumor – is it growing slowly or aggressively?

Determine the success of surgery – was the entire tumor removed during surgery? Is there residual disease? What are the chances of recurrence?

Predict therapy response – provide understanding of how the tumor will likely respond to various therapies.

Treatment monitoring – determine whether a patient is responding to therapy or requires treatment.


Companion Diagnostic to Predict Response to Peptide Receptor Radionuclide Therapy

The PRRT Predictive Quotient, or PPQ, is a companion diagnostic to the NETest developed to predict a patient’s response to peptide receptor radionuclide therapy (PRRT) for bronchopulmonary and gastroenteropancreatic neuroendocrine cancer. The test is based on an algorithm that combines information from 8 targeted genes (a subset of the NETest) and the histological grade of the neuroendocrine tumor.

PRRT in Practice

PPQ is an accurate (>96%) predictor of patient response to PRRT

PPQ Responders vs Non Responders

PPQ classifies patients as either “Responders,” who will experience NET disease stabilization and have a longer time to progression (usually greater than 18 months after the end of PRRT), or as “Non-responders”, who will experience a shorter time until the disease progresses (usually less than 12 months after the start of PRRT). Patients predicted as “Non-responders” may require additional or alternate therapies to stabilize their disease.

Research has shown that PPQ can predict a patient’s response to PRRT therapy with 96% accuracy, as recently demonstrated research published in the April, 2023 Journal of Nuclear Medicine.

NETest Fast Facts

The NETest helps you know more about a Neuroendocrine Tumor Diagnosis

Has been the subject of over 60 academic papers, peer-reviewed studies, and articles in medical journals.

Delivers higher levels of sensitivity, specificity, and accuracy than any other testing method available today.

Helps oncologists and patients manage and monitor treatment and quickly detect disease recurrence.

The NETest has been commercially available for almost 10 years and has been utilized over 10,000 times.

Ordering a NETest is simple

After discussing with your doctor or oncologist, use the button below to link to the Requisition Input form page. If you (or your doctor) have any questions about sample preparation or the sample submission process, click the NETest Sample Process button below.

Questions? Contact us via email or call (203) 208-3464

Frequently Asked Questions

Answering your questions

Our Frequently Asked Questions section provides answers to the most common questions. If your question isn’t answered, either contact us or feel free to submit the question and we will answer it and add it to the FAQ.


A less invasive, more accurate blood-based Prostate Cancer Diagnostic.

We have developed a multi-mRNA liquid biopsy biomarker assay that can help detect and define the molecular pathology of prostate cancer with a simple blood test.

Our blood-based PROSTest is a non-invasive prostate biopsy equivalent and can accurately detect, with greater than 90% confidence, the presence of prostate cancer gene markers in an easily obtained blood sample. Like our NETest, this biomarker assay plays a crucial role in characterizing the molecular pathology of prostate cancer for treatment guidance and monitoring.

The PROSTest is currently an “Investigational-use” diagnostic not commercially available to the general public. For more informational about it, please email us. 


Benefits and Differentiators

Far Less Invasive: unlike a tissue biopsy, which relies on harvested prostate tissue, our diagnostic is based on a drop of blood.

Highly accurate: significantly outperforming PSA and with greater than 95% accuracy in differentiating prostate cancer from benign prostatic hyperplasia.

Greater confidence:  provides information needed for greater confidence in commencing both initial and follow-up treatment.

The NETest

In The News

Our lab, our methodology, and our tests have been the subject of significant research, peer-reviewed papers, and media coverage.  Most recently, we received featured news coverage in the March issue of the Journal of Nuclear Medicine which characterized our PPQ as an effective predictor in determining whether PRRT can be used to treat a patient with neuroendocrine tumors. The NETest accurately monitored treatment response in real-time.